David Sourdive

Co-Founder, Executive Vice President CMC & Manufacturing • Cellectis

David Sourdive, PhD, is a co-founder of Cellectis and joined the Board of Directors in 2000. Dr Sourdive combines strong scientific expertise with experience in managing industrial programs bringing innovative technologies to industrial fruition. He served as Executive Vice President, Corporate Development, from 2008 to 2016 and as Executive Vice President, Technical Operations until July 2019. In addition to his role at Cellectis, Dr Sourdive has also served on the Mediterranean Institute for Life Sciences’ board of directors. David Sourdive graduated from École Polytechnique, received his PhD in molecular virology at Institut Pasteur and completed a research fellowship in the Emory University Department of Microbiology and Immunology. His management training is from the HEC (Challenge +) and his decade-long experience in industrial program management was acquired at the French Department of Defense (DGA) prior to Cellectis’ inception.

Also speaking

Jacqueline Barry

Chief Clinical Officer • CGT Catapult

Ann-Hunter Van Kirk

Senior Equity Research Analyst Biopharmaceuticals • Bloomberg Intelligence

Takis Athanasopoulos

Chief Executive Officer, Gene & Cell Ltd., Vice President, Gene Therapy Research & Vector Technology • ViGeneron

Event Info


Pre-Day Events

Discover more about the Pre-Day Events taking place at Advanced Therapies Europe.

2023 Sample Attendee List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.